[18, 22-24] Previous studies have shown that pretreatment IP-10 concentrations were closely associated with SVR rate in response to PEG IFN and RBV in patients with HCV genotype 1, with high systemic IP-10 concentrations at the onset of treatment predictive of poorer outcomes.[17, 18, 25] IL28B genotype in combination with IP-10 concentration

is useful for predicting SVR in patients with HCV genotype 1 with PEG IFN and RBV.[26] It has not been determined, however, whether IL28B genotype in combination with baseline IP-10 Navitoclax is useful in predicting outcomes in HCV-infected patients treated with TVR-based triple therapy.[27] This study was therefore designed to determine whether baseline serum IP-10 concentration is predictive of response to TVR-based triple therapy in patients with HCV genotype 1, and to examine the association between pretreatment

serum IP-10 concentration and other baseline patient characteristics. Between January 2012 and April 2013, 105 DAA-naïve patients with CHC were treated with TVR-based triple therapy at the Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Japan; the Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Quizartinib concentration Hyogo, Japan; and the Department of Hepatology, Osaka City University Hospital, Osaka, Japan. Pretreatment serum samples had been obtained from 100 of these patients and stored at −80°C. Three patients co-infected with HCV and hepatitis B virus were excluded; thus, 97 patients were analyzed.

All patients analyzed had compensated liver disease, were infected with HCV genotype 1, were naïve to DAA treatment, had no evidence of HIV infection, and had a serum learn more HCV RNA concentration of more than 5.0 log IU/mL. Liver biopsy samples obtained from 85 patients (87.6%) before treatment were coded and scored using the METAVIR scoring system by a single pathologist in each hospital.[28] Advanced fibrosis was defined as the presence of F3 or F4 fibrosis. The associations between baseline serum IP-10 concentration and the clinical characteristics and virological responses of patients were analyzed retrospectively. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of each participating facility. Written informed consent was obtained from all patients prior to treatment. All patients analyzed were scheduled to receive TVR (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan) in combination with PEG IFN-α-2b (Peg-Intron; MSD, Tokyo, Japan; 1.5 μg/kg per week) and weight-based RBV (Rebetol; MSD; total doses of 600 mg/day, 800 mg/day and 1000 mg/day for patients weighing less than <60 kg, 60–80 kg and >80 kg, respectively, according to Japanese guidelines) for 12 weeks, followed by PEG IFN-α-2b and RBV for 12 weeks.